Printer Friendly

Oncolytics announces issuance of 2nd European patent.

Oncolytics Biotech, Inc. (Calgary, Canada) has been granted European Patent 1,309,672 entitled "Method of Producing Infectious Reovirus." The claims relate to a method of producing infectious mammalian reovirus which is suitable for clinical administration to mammals including humans.

"This patent is consistent with our strategy to continue to expand and strengthen our portfolio of intellectual property worldwide," said Dr. Matt Coffey, Chief Scientific Officer for Oncolytics. "Along with our clinical trial and collaborative research programs in Europe, the United States and Canada, these patents are a key component of our development strategy for REOLYSIN."

Oncolytics is a biotechnology company focused on the development of REOLYSIN, its proprietary formulation of the human reovirus, as a potential cancer therapeutic. Oncolytics' researchers have demonstrated that the reovirus is able to selectively kill cancer cells and, in vitro, kill human cancer cells that are derived from many types of cancer including breast, prostate, pancreatic, bladder and brain tumours, and have also demonstrated successful cancer treatment results in a number of animal models. Phase I clinical trial results have indicated that REOLYSIN was well tolerated and that the reovirus demonstrated activity in tumours injected with REOLYSIN.

Oncolytics Biotech, Inc.

COPYRIGHT 2005 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Geographic Code:1CANA
Date:Aug 1, 2005
Previous Article:Sigma-Aldrich licenses fundamental RNAi patent estate from Alnylam.
Next Article:Alfred E. Mann Foundation obtains United States patent.

Related Articles
Oncolytics announces issuance of first Canadian patent - continues to strengthen intellectual property.
Oncolytics issued Canadian reovirus patent.
Oncolytics announces issuance of third Canadian patent covering use of the reovirus to treat cancers.
Oncolytics announces issuance of second Canadian patent - therapeutic use of the reovirus for cellular proliferative disorders including cancer.
Oncolytics announces issuance of patent for reovirus clearance of ras-mediated neoplastic cells.
Oncolytics announces issuance of 15th United States patent.
Oncolytics announces issuance of 15th United States patent.
Oncolytics Biotech announces issuance of 21th United States patent.
Oncolytics Biotech announces issuance of 6th Canadian patent.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters